BioRestorative Therapies (BRTX) Current Assets (2010 - 2025)
BioRestorative Therapies' (BRTX) quarterly Current Assets came in at $3.1 million in Q4 2025, down 71.85% YoY from $11.1 million in Q4 2024, and down 33.36% on a QoQ basis from $4.7 million in Q3 2025.
BioRestorative Therapies (BRTX) Current Assets (2010 - 2025) Analysis & Trends
BioRestorative Therapies (BRTX) has 16 years of Current Assets data on file, last reported at $3.1 million in Q4 2025.
- Quarterly Current Assets fell 71.85% year-over-year to $3.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.1 million (down 71.85% YoY) and the FY2025 annual result came in at $3.1 million, down 71.85% from the prior year.
- Current Assets fell to $3.1 million in Q4 2025, from $4.7 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $21.5 million in Q4 2021 to a low of $1.2 million in Q3 2021.
- A 5-year average of $11.4 million and a median of $12.3 million in 2023 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2021 — Current Assets surged 4794.93% — and 2025, when it plunged 71.85%.
- Tracing BRTX's Current Assets over 5 years: stood at $21.5 million in 2021, then slipped by 29.53% to $15.1 million in 2022, then decreased by 24.71% to $11.4 million in 2023, then fell by 2.16% to $11.1 million in 2024, then sank by 71.85% to $3.1 million in 2025.
- The last three Current Assets figures came in at $3.1 million (Q4 2025), $4.7 million (Q3 2025), and $7.6 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.62 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.63 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.76 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 18.80 Bn |
| 10 | BioRestorative Therapies | 2.00 Mn | -953,752.60 | 17,964.00 | 3.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.14 Mn |
| Sep 30, 2025 | 4.71 Mn |
| Jun 30, 2025 | 7.60 Mn |
| Mar 31, 2025 | 9.36 Mn |
| Dec 31, 2024 | 11.14 Mn |
| Sep 30, 2024 | 13.51 Mn |
| Jun 30, 2024 | 15.00 Mn |
| Mar 31, 2024 | 16.77 Mn |
| Dec 31, 2023 | 11.39 Mn |
| Sep 30, 2023 | 12.60 Mn |
| Jun 30, 2023 | 12.04 Mn |
| Mar 31, 2023 | 12.78 Mn |
| Dec 31, 2022 | 15.13 Mn |
| Sep 30, 2022 | 16.89 Mn |
| Jun 30, 2022 | 18.32 Mn |
| Mar 31, 2022 | 19.88 Mn |
| Dec 31, 2021 | 21.47 Mn |
| Sep 30, 2021 | 1.17 Mn |
| Jun 30, 2021 | 1.83 Mn |
| Mar 31, 2021 | 2.59 Mn |